As of this writing, the role of PD-L1 inhibitors in prostate cancer remains limited to a subset of patients with metastatic microsatellite instability-high, mismatch repair-deficient, or tumor ...

The results of this phase III KEYNOTE-991 study do not support the addition of pembrolizumab to enzalutamide and ADT for the treatment of mHSPC,” researchers wrote.

Launch prices for self-administered targeted anticancer therapies have grown precipitously,” researchers wrote.

Apotex has launched the first generic version of Tasigna (nilotinib), a TKI used to treat adult and pediatric patients with Ph+ CML.

Dozens of staff at the NIH walked out of a recent town hall meeting after Director Dr Jay Bhattacharya suggested the agency may have helped fund research that caused the COVID-19 pandemic.

The FDA expects that randomized, controlled trial data on clinical outcomes will be needed before COVID-19 vaccines can be approved for patients who are 6 months to 64 years of age and do not have ...

The median time to treatment initiation across all cancer types increased from 21 days in 2004 to 28 days in 2015. The median time to treatment initiation is increasing across cancer types, and this ...

We need to rethink our approach in responding to cancers in our younger women patients,” said Hope S. Rugo, MD.

These findings support the need for a phase III randomized controlled trial to definitively determine whether the addition of an antiangiogenic to a second or even a third-generation TKI provides ...

Cancer organizations are urging researchers, oncologists, and other stakeholders to advocate for cancer research.